216 related articles for article (PubMed ID: 34521418)
1. Patterns, trends and determinants of medical opioid utilization in Canada 2005-2020: characterizing an era of intensive rise and fall.
Jones W; Kaoser R; Fischer B
Subst Abuse Treat Prev Policy; 2021 Sep; 16(1):65. PubMed ID: 34521418
[TBL] [Abstract][Full Text] [Related]
2. Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005-2016.
Fischer B; Jones W; Vojtila L; Kurdyak P
Pain Physician; 2018 May; 21(3):219-228. PubMed ID: 29871366
[TBL] [Abstract][Full Text] [Related]
3. Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: an update with a focus on recent interventions.
Fischer B; Jones W; Rehm J
BMC Health Serv Res; 2014 Feb; 14():90. PubMed ID: 24572005
[TBL] [Abstract][Full Text] [Related]
4. Trends in dispensing of individual prescription opioid formulations, Canada 2005-2020.
Jones W; Kaoser R; Rudoler D; Fischer B
J Pharm Policy Pract; 2022 Mar; 15(1):27. PubMed ID: 35351208
[TBL] [Abstract][Full Text] [Related]
5. Correlations between population-levels of prescription opioid dispensing and related deaths in Ontario (Canada), 2005-2016.
Fischer B; Jones W; Varatharajan T; Malta M; Kurdyak P
Prev Med; 2018 Nov; 116():112-118. PubMed ID: 30217407
[TBL] [Abstract][Full Text] [Related]
6. Tramadol dispensing patterns and trends in Canada, 2007-2016.
Fischer B; Kurdyak P; Jones W
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):396-400. PubMed ID: 30548353
[TBL] [Abstract][Full Text] [Related]
7. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010.
Fischer B; Jones W; Krahn M; Rehm J
Pharmacoepidemiol Drug Saf; 2011 Dec; 20(12):1269-77. PubMed ID: 21755568
[TBL] [Abstract][Full Text] [Related]
8. Prescription opioid dispensing in Canada: an update on recent developments to 2018.
Jones W; Vojtila L; Kurdyak P; Fischer B
J Pharm Policy Pract; 2020; 13():68. PubMed ID: 33110608
[TBL] [Abstract][Full Text] [Related]
9. Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada.
Fischer B; Jones W; Tyndall M; Kurdyak P
BMC Public Health; 2020 Jan; 20(1):143. PubMed ID: 32005211
[TBL] [Abstract][Full Text] [Related]
10. Examining correlations between opioid dispensing and opioid-related hospitalizations in Canada, 2007-2016.
Jones W; Kurdyak P; Fischer B
BMC Health Serv Res; 2020 Jul; 20(1):677. PubMed ID: 32698815
[TBL] [Abstract][Full Text] [Related]
11. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims.
Karanges EA; Blanch B; Buckley NA; Pearson SA
Br J Clin Pharmacol; 2016 Jul; 82(1):255-67. PubMed ID: 26991673
[TBL] [Abstract][Full Text] [Related]
12. Correlations between Changes in Medical Opioid Dispensing and Contributions of Fentanyl to Opioid-Related Overdose Fatalities: Exploratory Analyses from Canada.
Jones W; Lee MA; Kaoser R; Fischer B
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299958
[TBL] [Abstract][Full Text] [Related]
13. Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010.
Murphy Y; Goldner EM; Fischer B
Pain Physician; 2015; 18(4):E605-14. PubMed ID: 26218951
[TBL] [Abstract][Full Text] [Related]
14. Trends and uptake of new formulations of controlled-release oxycodone in Canada.
Gomes T; Jain S; Paterson JM; Sketris I; Caetano P; Henry D;
Pharmacoepidemiol Drug Saf; 2018 May; 27(5):520-525. PubMed ID: 29359446
[TBL] [Abstract][Full Text] [Related]
15. Anticipating the effects of restricting high-dose preparations of strong opioids in Australia: A population-based analysis to inform the current policy debate.
Zheng D; Narayan SW; Zoega H; Litchfield M; Buckley NA; Pearson SA; Schaffer AL
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):521-527. PubMed ID: 30790376
[TBL] [Abstract][Full Text] [Related]
16. Trends in high-dose opioid prescribing in Canada.
Gomes T; Mamdani MM; Paterson JM; Dhalla IA; Juurlink DN
Can Fam Physician; 2014 Sep; 60(9):826-32. PubMed ID: 25217680
[TBL] [Abstract][Full Text] [Related]
17. State-to-State Variation in Opioid Dispensing Changes Following the Release of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain.
Lyu X; Guy GP; Baldwin GT; Losby JL; Bohnert ASB; Goldstick JE
JAMA Netw Open; 2023 Sep; 6(9):e2332507. PubMed ID: 37695587
[TBL] [Abstract][Full Text] [Related]
18. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review.
Fischer B; Argento E
Pain Physician; 2012 Jul; 15(3 Suppl):ES191-203. PubMed ID: 22786457
[TBL] [Abstract][Full Text] [Related]
19. Trends in State-Level Pharmacy-Based Naloxone Dispensing Rates, 2012-2019.
Guy GP; Khushalani JS; Jackson H; Sims RSC; Arifkhanova A
Am J Prev Med; 2021 Dec; 61(6):e289-e295. PubMed ID: 34801208
[TBL] [Abstract][Full Text] [Related]
20. Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011.
Fischer B; Jones W; Urbanoski K; Skinner R; Rehm J
Drug Alcohol Rev; 2014 Jan; 33(1):19-26. PubMed ID: 24261474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
